Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 666

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 666
---
 traded holding company for its subsidiary. On March 18, 2024, Heritas Cayco formally changed its name to OmnigenicsAI Corp. On February 26, 2024, the Company underwent a reorganization pursuant to which Heritas Ltd., an exempted company organized under the laws of the Cayman Islands, contributed to OmnigenicsAI a wholly owned subsidiary of Heritas Ltd., all the issued and outstanding shares in its subsidiary, Heritas SAU (“Heritas Argentina”). Heritas SAU, officially formed on July 10, 2015, is a company incorporated and domiciled in Argentina. Together, OmnigenicsAI and its subsidiary, Heritas SAU, are referred to as the “Group.” As a result of this contribution, Heritas Argentina became a wholly owned subsidiary of OmnigenicsAI. In exchange for this contribution, OmnigenicsAI issued 30,000,000shares with a par value of US$0.0001 per share to Heritas Ltd., thereby completing the reorganization. This entailed, in the year ended June 30, 2024, a reduction of the share capital from US$13,059 to US$3,000. The effect of the reduction in share capital by US$10,059 and the related inflation adjustment on share capital of US$39,826 was impacted by an offsetting in share premium in accordance with the movement identified as “Reorganization effects” in the Combined Statement of Changes in Shareholders’ Deficit. On March 25, 2024, the Company entered into a Business Combination Agreement (“BCA”) with APx Acquisition Corp. I (“SPAC”), Heritas Merger Sub Limited and MultiplAI Health Ltd., a private limited company formed under the laws of England and Wales, to effectuate a business combination. The transaction, designed to transition OmnigenicsAI into a publicly traded entity, involves the merger of Heritas Merger Sub Limited, a wholly -ownedsubsidiary of OmnigenicsAI incorporated in the Cayman Islands, with and into SPAC, a company also incorporated in the Cayman Islands, with SPAC continuing as the surviving entity and becoming a wholly -ownedsubsidiary of OmnigenicsAI. As part of the transaction, all SPAC shares and warrants will convert into equity in OmnigenicsAI, pursuant to the terms of the BCA. Within the framework of the BCA, an agreement has been reached, which is conditional on the closing of